This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| INSERM Unit 1149 | |
|---|---|
| Name | INSERM Unit 1149 |
| Established | 2010s |
| Type | Biomedical research unit |
| Location | Paris, France |
| Parent | Institut national de la santé et de la recherche médicale |
INSERM Unit 1149 is a biomedical research unit based in Paris affiliated with the Institut national de la santé et de la recherche médicale and local university hospitals. The unit concentrates on translational research bridging molecular biology, clinical neurology, and genetics with an emphasis on neurodegenerative and neurodevelopmental disorders. It engages with national and international partners across academic institutions, hospitals, and industry to advance diagnostics, therapeutics, and biomarker discovery.
Established during a period of restructuring within the Institut national de la santé et de la recherche médicale, the unit emerged amid initiatives connected to flagship programs such as the France 2030 plan, partnerships involving the Assistance Publique–Hôpitaux de Paris, and university research federations. Founding efforts drew on expertise from groups active in projects tied to the European Research Council, Agence nationale de la recherche, and major hospital centers including Hôpital Pitié-Salpêtrière and Hôpital Necker–Enfants Malades. Over time the unit has participated in collaborative networks responding to calls like Horizon 2020 and Horizon Europe, contributing to consortia with institutions such as Sorbonne University, Université Paris Cité, and academic hospitals across Île-de-France.
The unit's core research spans molecular genetics, neurobiology, and clinical translational science with programs targeting Alzheimer's disease, Parkinson's disease, autism spectrum disorders, and rare genetic encephalopathies. Investigations incorporate next-generation sequencing platforms used in collaborations with EMBL and Wellcome Trust–funded initiatives, single-cell transcriptomics linked to projects at the Broad Institute and CNRS laboratories, and proteomics pipelines akin to those at the Max Planck Institute. Research lines emphasize biomarker development relevant to clinical trials run in partnership with pharmaceutical companies such as Sanofi and Roche, and therapeutic approaches informed by gene therapy advances from institutions like the University of Oxford and Massachusetts General Hospital.
The unit is structured into thematic teams combining principal investigators, clinicians, postdoctoral fellows, and technical staff drawn from affiliated hospitals and universities. Leadership typically includes a director with a background in clinical neurology, deputies with expertise in genetics and bioinformatics, and administrative officers coordinating relations with national agencies including INSERM headquarters and university research services. Scientific committees mirror governance models seen at institutions like Institut Pasteur and Karolinska Institutet, and advisory boards often feature external members from institutions such as Columbia University, University College London, and ETH Zurich.
Collaborative partners encompass French and international academic centers, hospital networks, and industrial partners. Notable linkages include consortia with Sorbonne University, Université Paris Cité, Assistance Publique–Hôpitaux de Paris, CNRS units, and international collaborators at University of Cambridge, Johns Hopkins University, and the University of Toronto. The unit participates in European collaborative frameworks resembling networks organized under the European Molecular Biology Laboratory, the Human Brain Project, and EATRIS, and engages with patient advocacy groups comparable to the Alzheimer's Association and the European Huntington's Disease Network.
Laboratory infrastructure supports genomic sequencing, imaging, and cellular models with core facilities similar to those at the Institut Pasteur, including high-throughput sequencers, confocal and two-photon microscopy suites, and biosafety level platforms used in translational neuroscience. Access to clinical research centers provides biobanking capabilities aligned with standards from BBMRI-ERIC and clinical trial units modeled after those at CHU Grenoble Alpes and Hôpital Cochin. Computational resources support bioinformatics pipelines comparable to those implemented at the European Bioinformatics Institute and national supercomputing centers.
Funding derives from national competitive grants awarded by Agence nationale de la recherche, targeted calls from the French Ministry of Health, European grants under Horizon Europe, as well as philanthropy and industry-sponsored research agreements with biopharmaceutical firms and foundations akin to Fondation pour la Recherche Médicale and the Gates Foundation. The unit has secured project-based funding through mechanisms similar to European Research Council investigator grants and collaborative grants reflecting public–private partnership models used by Inserm and partner universities.
The unit has contributed to high-impact publications in journals comparable to Nature, Science, Neuron, and The Lancet Neurology, reporting findings on genetic determinants of neurodevelopmental disorders, biomarker panels for neurodegeneration, and translational studies that informed early-phase clinical trials. Achievements include development of diagnostic pipelines adopted by clinical genetics services, participation in multicenter trials echoing efforts at Mayo Clinic and Cleveland Clinic, and training of researchers who have moved to leadership roles at institutions such as University of Oxford, Harvard Medical School, and Karolinska Institutet. Category:Research institutes in France